Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 1245b is a short, non-coding RNA molecule (20-24 nucleotides) classified within the microRNA family and encoded in the human genome. Like other microRNAs, it is produced through canonical miRNA biogenesis involving Drosha and Dicer, is incorporated into the RNA-induced silencing complex (RISC), and functions by binding (imperfectly) to target mRNA transcripts—most commonly in their 3' UTR—to modulate translation and stabilize mRNA. MIR1245B is predicted to participate in post-transcriptional regulation of gene expression, but its precise biological roles, therapeutic relevance, and disease associations remain largely uncharacterized. It is affiliated with Herpes simplex virus keratitis and genital herpes by gene association but lacks mechanistic or functional studies supporting a drug target or biomarker role[1][3][4].
No drugs targeting this microRNA; mechanism refers to endogenous function as a miRNA: binding target mRNAs, leading to translation inhibition or mRNA degradation[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 1245b (MIR1245B).